JCR Pharma 2026 Earnings Outlook and Financial Summary | June 2026

Performance Summary

In FY2025, sales were 33,072 million yen, a decrease of 22.9% from the previous year, but for FY2026, sales are projected to be 37,800 million yen, with an expected increase. R&D expenses increased to 15.4 billion yen, and an operating profit of 2.6 billion yen is planned for the next period. The main products, such as the mucopolysaccharidosis treatment drug "Izargo®" and growth hormone preparations, have continued steady sales, and proactive R&D is underway for future growth. Financially, total assets are 104.8 billion yen, net assets are 47.7 billion yen, and the equity ratio is 45.1%.

Outlook and Impact on Shareholders

The next period forecasts sales of 37,800 million yen, an operating profit of 2.6 billion yen, and net profit of 3 billion yen, with continued emphasis on R&D investments to strengthen the earnings base. Dividends are planned to remain at 20 yen per share. Through funding progress and new drug development, the company aims for long-term growth and shareholder returns. The company is also continuously considering share buybacks and capital policies to suppress share dilution and enhance corporate value.